SHH and chronic myelogenous leukemia, BCR-ABL1 positive: Through this we will be able to efficiently differentiate and identify markers for therapeutic response between NSCLC‐ squamous and ‐adenocarcinoma; among Wnt‐, SHH‐, Group‐3‐ and Group‐4‐Medulloblastoma; and between TKI sensitive and TKI‐resistant CML cases.